-
InxMed’s Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC Treatment in China
•
China-based InxMed (Nanjing) Co., Ltd has announced that the Center for Drug Evaluation of the National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) to its innovative small-molecule ifebemtinib (IN10018). The designation is for the use of ifebemtinib, a focal adhesion kinase (FAK) inhibitor, in combination with…
-
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
•
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs). Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit…
-
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
•
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule FAK inhibitor ifebemtinib (IN10018) at the European Society for Medical Oncology (ESMO) Congress 2023. The studies evaluated the drug’s efficacy and safety in treating platinum-resistant recurrent ovarian cancer and advanced triple negative breast cancer. Phase…
-
InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs
•
China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum Healthcare. Under the terms of the agreement, GeneQuantum will grant InxMed a non-exclusive license to utilize its independently developed and globally leading core coupling technologies for the development of innovative antibody drug conjugates (ADCs). Access…
-
InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy
•
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical Co., Ltd to collaborate on pre-clinical and clinical studies for a combination therapy targeting various solid tumors. The partnership will focus on combining InxMed’s IN10018, a selective oral inhibitor of focal adhesion kinase (FAK), with…
-
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
•
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt financing from SPD Silicon Valley Bank. The funding will support the development of IN10018 (BI853520), a focal adhesion kinase (FAK) inhibitor licensed from iPharma Ltd and Boehringer Ingelheim. Drug ProfileIN10018 is under clinical investigation in…
